If you have been reading about REV-ERB agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-05. Numbers and descriptions here follow the published literature rather than marketing material.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
A soldier going to battle on Pervitin usually found himself unable to perform effectively for the next day or two. Suffering from a drug hangover and looking more like a zombie than a great warrior, he had to recover from the side effects. Some soldiers turned violent, committing war crimes against civilians; others attacked their own officers. At the end of the war, it was used as part of a new drug: D-IX. Obetrol, patented by Obetrol Pharmaceuticals in the 1950s and indicated for treatment of obesity, was one of the first brands of pharmaceutical methamphetamine products. Because of the psychological and stimulant effects of methamphetamine, Obetrol became a popular diet pill in the United States in the 1950s and 1960s. Eventually, as the addictive properties of the drug became known, governments began to strictly regulate the production and distribution of methamphetamine. For example, during the early 1970s in the United States, methamphetamine became a schedule II controlled substance under the Controlled Substances Act. As of January 2013, the Desoxyn trademark had been sold to Italian pharmaceutical company Recordati.
According to James B. Harrod humankind first developed religious and spiritual beliefs during the Middle Paleolithic or Upper Paleolithic. Controversial scholars of prehistoric religion and anthropology, James Harrod and Vincent W. Fallio, have recently proposed that religion and spirituality (and art) may have first arisen in Pre-Paleolithic chimpanzees or Early Lower Paleolithic (Oldowan) societies. According to Fallio, the common ancestor of chimpanzees and humans experienced altered states of consciousness and partook in ritual, and ritual was used in their societies to strengthen social bonding and group cohesion. Middle Paleolithic humans' use of burials at sites such as Krapina, Croatia (c. 130,000 BP) and Qafzeh, Israel (c. 100,000 BP) have led some anthropologists and archaeologists, such as Philip Lieberman, to believe that Middle Paleolithic humans may have possessed a belief in an afterlife and a "concern for the dead that transcends daily life". Cut marks on Neanderthal bones from various sites, such as Combe-Grenal and Abri Moula in France, suggest that the Neanderthals—like some contemporary human cultures—may have practiced ritual defleshing for (presumably) religious reasons. According to recent archaeological findings from Homo heidelbergensis sites in Atapuerca, humans may have begun burying their dead much earlier, during the late Lower Paleolithic; but this theory is widely questioned in the scientific community.
Innovations continued through the Middle Ages with the introduction of silk production (in Asia and later Europe), the horse collar, and horseshoes. Simple machines (such as the lever, the screw, and the pulley) were combined into more complicated tools, such as the wheelbarrow, windmills, and clocks. A system of universities developed and spread scientific ideas and practices, including Oxford and Cambridge. The Renaissance era produced many innovations, including the introduction of the movable type printing press to Europe, which facilitated the communication of knowledge. Technology became increasingly influenced by science, beginning a cycle of mutual advancement.
Sources: en.wikipedia.org
==== Secondary-Ion MS ==== SIMS is a micro-analytical technique valuable for three-dimensional analysis of a materials elemental composition and isotopic ratios. This method can be utilized in characterization of bulk materials with a detection limit in the low parts per billion (10−9 or ng/g) range. Particles as small as a few hundreds of nanometers can be detected. Ion production in this technique is dependent on the bombardment of solid samples with a focused beam of primary ions. The sputtered, secondary ions are directed onto the mass spectrometry system to be measured. The secondary ions are a result of kinetic energy transfer from the primary ions. These primary ions penetrate into the solid sample to some depth. This method can be used to detect any element, however the sputtering process is highly matrix dependent and ion yields vary. This method is especially useful, because it can be fully automated to find uranium particles in a sample of many million particles in a matter of hours. Particles of interest can then be imaged and further analyzed with very high isotopic precision.
== Adverse effects == Nutmeg intoxication is accompanied by unpleasant physical effects and feeling sick. Adverse effects of nutmeg have been reported to include malaise, nausea, vomiting, abdominal pain, dizziness, dry mouth, thirst, pupil constriction, skin flushing, reddening of the eyes, tachycardia, weak pulses, heart palpitations, hypotension, cold extremities, cyanosis, pallor, dyspnea, hypothermia, drowsiness, sedation, feeling heavy, lethargy, hyperactivity, agitation or restlessness, motor impairment, incoherent speech, loss of memory, stupor, delirium, insomnia, deep sleep, unconsciousness, and feelings and fears of impending death. After-effects are also said to be quite unpleasant and to include not feeling right, bone and muscle aches, eye soreness and aches, runny nose, tiredness, depression, and headaches. While some people may enjoy nutmeg intoxication, most find it to be a "rather grueling" experience, to be "too unpleasant to be addicting", and even to cause prolonged aversion to the spice.
=== News and information === TikTok is becoming a growing source of news for Americans. Pew Research Center found that the percentage of US adults who regularly got their news from TikTok more than tripled from 3% of US adults in 2020, to 10% in 2022, and now 14% in 2023. The percentage of US adult TikTok users who regularly get their news from the platform increased from 22% to 33% in the same time period. This is much lower than the percentage of Facebook and Twitter users who regularly get their news from those platforms. However, unlike with TikTok, the proportion of Facebook and Twitter users who get their news from those platforms declined every year from 2020 to 2022. An increasing proportion of Generation Z internet users have also started using TikTok as their preferred search engine over Google.
Free nerve ending A type of unencapsulated nerve ending that detects pain, temperature, and crude touch. These are the most common type of cutaneous receptors. Frontal lobe A region of the cerebral cortex involved in decision-making, planning, motor function, problem-solving, and aspects of personality. Located at the front of each cerebral hemisphere. Frontal eye fields A region in the frontal lobe involved in voluntary eye movements and visual attention. It plays a role in saccadic control and visual tracking. Functional connectivity A measure of how different brain regions interact during rest or tasks, often assessed using fMRI or EEG by examining correlations in activity over time. Functional magnetic resonance imaging (fMRI) A neuroimaging technique that measures brain activity by detecting changes in blood oxygenation (BOLD signal). It is used to study brain function in real time. Fusiform gyrus A brain region located in the temporal and occipital lobes involved in high-level visual processing, including facial recognition and object categorization. Fusiform face area (FFA) A specialized part of the fusiform gyrus that responds selectively to faces. It is often studied in the context of prosopagnosia (face blindness) and visual expertise.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.